Keros Therapeutics Inc
KROS
Get informed when a big investor buys or sells
+ FollowMarket Cap$236.93M
Close$
$13.60
22.5% upside
Current Fair Value
22.5% upsideUndervalued by 22.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $236.93 Million |
|---|---|
| Enterprise Value | $-4,947,103.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.34 |
| Beta | 1.02 |
| Outstanding Shares | 19,800,322 |
Return
| Return on Equity | -31.70% |
|---|---|
| Return on Assets | -28.91% |
| Return on Invested Capital | -39.99% |
Valuation & Multiples
| P/E Ratio | -3.23 |
|---|---|
| PEG | 49.92 |
| Price to Sales | - |
| Price to Book Ratio | 0.85 |
| Enterprise Value to Revenue | -0.33 |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -3.18 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.34
Average shareholder expectationRevenue Estimate
$828,571
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$14.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 94.49% |
|---|---|
| Total Invested | $30,404▼ 99.98% |
| Investors Holding | 3▼ 131.00% |
ESG Score
No data